Loading...
GSK logo

GSK plcNYSE:GSK Stock Report

Market Cap US$101.8b
Share Price
n/a
1Y35.2%
7D-0.8%
1D1.2%
Portfolio Value
​
View

GSK plc

NYSE:GSK Stock Report

Market Cap: US$101.8b

GSK (GSK) Stock Overview

Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details

GSK fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance4/6
Financial Health3/6
Dividends3/6

Rewards

Trading at 61.2% below our estimate of its fair value

Earnings are forecast to grow 5.12% per year

Earnings grew by 84.9% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results

Has a high level of debt

Unstable dividend track record


GSK Community Fair Values

Create Narrative

See what 60 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW483,974 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
483,974 investors already sharing narratives
View all narratives

GSK plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for GSK
Historical stock prices
Current Share PriceUK£51.35
52 Week HighUK£61.70
52 Week LowUK£36.75
Beta0.30
1 Month Change-2.19%
3 Month Change-5.29%
1 Year Change35.24%
3 Year Change44.89%
5 Year Change2.34%
Change since IPO-25.81%

Recent News & Updates

Seeking Alpha • Jun 25

Is GSK Quietly Becoming An Oncology Powerhouse

Summary GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and Jemperli, I believe Exdensur could become another meaningful growth driver. So, sales of Exdensur, a twice-yearly add-on maintenance treatment of severe asthma, were $15 million in its first full quarter following FDA approval. I will nextdiscuss other factors that, in my view, make GSK’s risk/reward profileattractive. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 25

Is GSK Quietly Becoming An Oncology Powerhouse

Summary GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and Jemperli, I believe Exdensur could become another meaningful growth driver. So, sales of Exdensur, a twice-yearly add-on maintenance treatment of severe asthma, were $15 million in its first full quarter following FDA approval. I will nextdiscuss other factors that, in my view, make GSK’s risk/reward profileattractive. Read the full article on Seeking Alpha

Shareholder Returns

GSKUS PharmaceuticalsUS Market
7D-0.8%1.8%-1.1%
1Y35.2%42.8%15.1%

Return vs Industry: GSK underperformed the US Pharmaceuticals industry which returned 42.8% over the past year.

Return vs Market: GSK exceeded the US Market which returned 15.1% over the past year.

Price Volatility

Is GSK's price volatile compared to industry and market?
GSK volatility
GSK Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement9.2%
Market Average Movement7.1%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: GSK has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: GSK's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
171566,841Luke Mielswww.gsk.com

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.

GSK plc Fundamentals Summary

How do GSK's earnings and revenue compare to its market cap?
GSK fundamental statistics
Market capUS$101.83b
Earnings (TTM)US$7.77b
Revenue (TTM)US$43.67b
13.1x
P/E Ratio
2.3x
P/S Ratio

Is GSK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GSK income statement (TTM)
RevenueUK£32.78b
Cost of RevenueUK£8.89b
Gross ProfitUK£23.89b
Other ExpensesUK£18.06b
EarningsUK£5.83b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 28, 2026

Earnings per share (EPS)1.46
Gross Margin72.87%
Net Profit Margin17.78%
Debt/Equity Ratio109.7%

How did GSK perform over the long term?

See historical performance and comparison

Dividends

3.8%
Current Dividend Yield
46%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/26 03:06
End of Day Share Price 2026/07/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GSK plc is covered by 47 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research
Xue ChenBarclays